Tvardi Therapeutics (TVRD)
NASDAQ:TVRD
Want to see TVRD full AI Analyst Report?
TVRD Stock Chart & Stats
$3.39
--
Market closed
$3.39
--
Day’s Range― - ―
52-Week Range$2.75 - $43.65
Previous CloseN/A
VolumeN/A
Average Volume (3M)401.55K
Market Cap
$32.74M
Enterprise Value$13.06M
Total Cash (Recent Filing)$30.81M
Total Debt (Recent Filing)$201.00K
Price to Earnings (P/E)―
Beta0.29
Next Earnings
Aug 13, 2026EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.38
Shares Outstanding9,381,344
10 Day Avg. Volume1,070,842
30 Day Avg. Volume401,545
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-1.36
Enterprise Value/Market Cap0.40
Enterprise Value/Revenue5.09
Enterprise Value/Gross Profit5.18
Enterprise Value/Ebitda-0.55
Forecast
1Y Price Target
$8.60Price Target Upside153.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Anti-fibrotic Clinical SignalsPhase 2 and post‑hoc analyses for TTI-101 showed consistent favorable trends across imaging, biomarkers, and lung function, supporting the potential for STAT3 inhibition to meaningfully reduce fibrosis and inflammation.
Next-generation Prodrug DesignTTI-109's prodrug approach is designed to convert to the active agent after entering the bloodstream while remaining inert in the gut, potentially improving solubility and gastrointestinal tolerability versus the parent molecule.
Oncology Activity And Dose OptimizationInterim hepatocellular carcinoma data demonstrated clinically meaningful single-agent and combination activity for TTI-101, indicating opportunity for dose optimization to enhance clinical benefit.
Bears Say
Gastrointestinal Tolerability And DiscontinuationsGastrointestinal-related adverse events drove treatment discontinuations and contributed to missed topline results, creating a clear tolerability issue that must be addressed to restore confidence in the program.
Research Objectivity And Conflicts Of InterestDisclosed business relationships between the covering firm and industry participants may create perceived conflicts of interest, which could affect the credibility and objectivity of analyst reports.
Trial Interpretability And Placebo PerformanceHigh discontinuation rates in the active arm and stronger-than-expected placebo performance complicated topline interpretation, increasing uncertainty about the true magnitude of the treatment effect.
Tvardi Therapeutics News
TVRD FAQ
What was Tvardi Therapeutics’s price range in the past 12 months?
Tvardi Therapeutics lowest stock price was $2.75 and its highest was $43.65 in the past 12 months.
What is Tvardi Therapeutics’s market cap?
Tvardi Therapeutics’s market cap is $32.74M.
When is Tvardi Therapeutics’s upcoming earnings report date?
Tvardi Therapeutics’s upcoming earnings report date is Aug 13, 2026 which is in 75 days.
How were Tvardi Therapeutics’s earnings last quarter?
Currently, no data Available
Is Tvardi Therapeutics overvalued?
According to Wall Street analysts Tvardi Therapeutics’s price is currently Undervalued.
Does Tvardi Therapeutics pay dividends?
Tvardi Therapeutics does not currently pay dividends.
What is Tvardi Therapeutics’s EPS estimate?
Tvardi Therapeutics’s EPS estimate is -0.7.
How many shares outstanding does Tvardi Therapeutics have?
Tvardi Therapeutics has 9,381,344 shares outstanding.
What happened to Tvardi Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tvardi Therapeutics?
Currently, no hedge funds are holding shares in TVRD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tvardi Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.60 (153.69% Upside)
$8.60 (153.69% Upside)
Hedge Fund Trend
Decreased
By 21.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-31.48%
12-Months-Change
Fundamentals
Return on Equity
-64.17%
Trailing 12-Months
Asset Growth
-33.71%
Trailing 12-Months
Company Description
Tvardi Therapeutics
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
TVRD Stock 12 Month Forecast
Average Price Target
$8.60
▲(153.69% Upside)
Technical Analysis
Plus Therapeutics
―
Cue Biopharma
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Adlai Nortye Ltd. Sponsored ADR
―
Ownership Overview
3.36% Insiders
7.92% Mutual Funds
11.87% Other Institutional Investors
70.45% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---